Drug Profile

Research programme: CD14 and lipopolysaccharide targeting peptide based therapeutics - Hunan Jiudian Pharmaceutical/Zonsen PepLib Biotech

Latest Information Update: 12 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 Feb 2026 Preclinical trials in Bacterial infections in China (unspecified route) prior to February 2026 (Zonsen PepLib Biotech pipeline, February 2026)
12 Feb 2026 Preclinical trials in Inflammation in China (unspecified route) prior to February 2026 (Zonsen PepLib Biotech pipeline, February 2026)
28 Feb 2024 CD14/Lipopolysaccharide targeting drug licensed to Hunan Jiudian Pharmaceutical worldwide

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com